Payment overview · 2025
General Payments
$377.20
19 reported records · 8 companies
Healthcare provider profile · identity verified
Macey Dodd, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MALTA, OH · NPI 1275199820
Verified facts
What the public records show
CMS Open Payments records show Macey Dodd, APRN received $377.20 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $112.51 | 29.8% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.36 | 17.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.01 | 13.0% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $34.00 | 9.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.27 | 8.3% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.04 | 8.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.59 | 7.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $25.42 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $343.20 | 18 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.36 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.79 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.79 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $49.72 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $49.01 | 2 | 2025 |
Source payment records
|
|||||
| Introducer Needle Normalized: introducer needle |
Device | Becton, Dickinson and Company | $34.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 149 | 50 |
| Gabapentin | Gabapentin | 139 | 45 |
| Lisinopril | Lisinopril | 135 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 133 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 41 |
| Methylprednisolone | Methylprednisolone | 110 | 89 |
| Furosemide | Furosemide | 109 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 34 |
| Potassium Chloride | Potassium Chloride | 73 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 26 |
| Eliquis | Apixaban | 58 | 18 |
| Omeprazole | Omeprazole | 57 | 19 |
| Trazodone Hcl | Trazodone Hcl | 56 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 18 |
| Alprazolam | Alprazolam | 53 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 16 |
| Memantine Hcl | Memantine Hcl | 53 | 18 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Losartan Potassium | Losartan Potassium | 51 | 19 |
| Sertraline Hcl | Sertraline Hcl | 48 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 18 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Metformin Hcl | Metformin Hcl | 35 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 33 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Baclofen | Baclofen | 31 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 18 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | 12 |
| Atenolol | Atenolol | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Ozempic | Semaglutide | 28 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | 13 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 17 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | 16 |
| Azithromycin | Azithromycin | 21 | 21 |
| Risperidone | Risperidone | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 16 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 16 |
| Primidone | Primidone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 11 |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | 11 |
| Carvedilol | Carvedilol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.20 · 19 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, CREON, Introducer Needle, LINZESS, NUZYRA, Ohtuvayre, QULIPTA, UBRELVY, VOQUEZNA, XHANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error